UCSD study reports significant neurological impacts of ‘long-haul’ COVID-19


The neurological impact of “long-haul” COVID-19 is significant, even six months after infection, according to the first round of research published by UC San Diego scientists.

The results, published June 15 in the Annals of Clinical and Translational Neurology, found various short- and long-term symptoms and, while many patients showed improvement, the majority still had some neurological symptoms half a year later. Additionally, a subset of people also exhibited significant coordination and cognitive issues that had not been previously described.

“It’s encouraging that most people were showing some improvement at six months, but that wasn’t the case for everyone,” said Dr. Jennifer Graves, senior author of the study and an associate professor at the UCSD School of Medicine and a neurologist at UCSD Health.

Following mild to moderate infections with SARS-CoV-2 — the coronavirus that causes COVID-19 — 56 people with neurological symptoms were recruited to the study between October 2020 and October 2021. They completed a neurological exam, a cognitive assessment, questionnaires and an optional brain scan. Baseline measurements were taken a few months after their initial infection and repeated three and six months later.

At the time of the first visit, 89 percent of participants were experiencing fatigue and 80 percent reported headaches. According to the research, other common neurological symptoms included memory impairment, insomnia and decreased concentration. Eighty percent said those symptoms affected their quality of life.

When participants returned for their six-month follow-up, only one-third reported complete resolution of symptoms. The remaining two-thirds reported persistent neurological symptoms, though most had diminished in severity. The most prevalent symptoms at six months were memory impairment and decreased concentration.

The authors wrote that none of the people with persistent symptoms at six months had any history of neurological conditions before their infections.

“Some of these participants are high-level professionals who we’d expect to score above average on cognitive assessments, but months after having COVID-19, they’re still scoring abnormally,” Graves said.

A surprising result was that 7 percent of participants displayed a previously unidentified set of symptoms that included cognitive deficits, tremors and difficulty balancing. The authors labeled that post-acute sequelae of COVID-19 infection with tremor, ataxia and cognitive deficit, or PASC-TAC.

“These are folks who had no neurological problems before COVID-19, and now they have an incoordination of their body and possible incoordination of their thoughts,” Graves said. “We didn’t expect to find this, so we want to get the word out in case other physicians see this, too.”

Research is continuing on how much SARS-CoV-2 directly invades the brain, but Graves said it is more likely that the delayed neurological symptoms are caused by the infection triggering an inflammatory autoimmune response in the brain.

The UCSD team plans to continue monitoring participants’ symptoms annually for up to 10 years. Additional efforts will evaluate how different COVID-19 variants and vaccines affect long-term neurological symptoms.

“To have people’s cognition and quality of life still impacted so long after infection is something we as a society need to be taking a serious look at,” Graves said. “We still need to know how common this is, what biological processes are causing this and what ongoing health care these people will need. This work is an important first step to getting there.” ◆